EC Number | Application | Comment | Organism |
---|---|---|---|
1.8.4.11 | medicine | MsrA efficiently reduces oxidized methionine residues in recombinant alpha-synuclein. Enhancing MsrA function may be a reasonable therapeutic strategy in Parkinson's disease | Bos taurus |
EC Number | Natural Substrates | Organism | Comment (Nat. Sub.) | Natural Products | Comment (Nat. Pro.) | Rev. | Reac. |
---|---|---|---|---|---|---|---|
1.8.4.11 | peptide-L-methionine (S)-S-oxide + thioredoxin | Bos taurus | MsrA suppresses dopaminergic cell death and protein aggregation induced by the complex I inhibitor rotenone or mutant alpha-synuclein, but not by the proteasome inhibitor MG132. MsrA protects against Parkinson's disease-related stresses primarily via methionine sulfoxide repair rather than by scavenging reactive oxygen species | peptide-L-methionine + thioredoxin disulfide + H2O | - |
? |
EC Number | Organism | UniProt | Comment | Textmining |
---|---|---|---|---|
1.8.4.11 | Bos taurus | P54149 | recombinant | - |
EC Number | Purification (Comment) | Organism |
---|---|---|
1.8.4.11 | - |
Bos taurus |
EC Number | Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|---|
1.8.4.11 | alpha-synuclein-L-methionine (S)-S-oxide + thioredoxin | - |
Bos taurus | alpha-synuclein-L-methionine + thioredoxin disulfide + H2O | - |
? | |
1.8.4.11 | peptide-L-methionine (S)-S-oxide + thioredoxin | MsrA suppresses dopaminergic cell death and protein aggregation induced by the complex I inhibitor rotenone or mutant alpha-synuclein, but not by the proteasome inhibitor MG132. MsrA protects against Parkinson's disease-related stresses primarily via methionine sulfoxide repair rather than by scavenging reactive oxygen species | Bos taurus | peptide-L-methionine + thioredoxin disulfide + H2O | - |
? |
EC Number | Synonyms | Comment | Organism |
---|---|---|---|
1.8.4.11 | methionine sulfoxide reductase A | - |
Bos taurus |
1.8.4.11 | MsrA | - |
Bos taurus |